VR Logo

Achilles Therapeutics plc (ACHL) download report


Healthcare | Biotechnology & Pharma Research

Achilles Therapeutics plc (ACHL) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors.

IPO Date: 31-Mar-2021

CEO & Director: Dr. Iraj Ali

Founder & Chief Medical Officer: Dr. Karl Peggs M.D.

Listing: NASDAQ: ACHL

Country: United Kingdom

Headquarters: London,

Website: https://www.achillestx.com

Key Facts

Market cap: $101.52 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-64.69 Mln

Cash: $236.93 Mln

Total Debt: $11.88 Mln

Insider's Holding: 4.92%

Liquidity: Low

52 Week range: $1.84 - 11.40

Shares outstanding: 40,771,000

Stock Performance

Time Period Achilles Therapeutics (ACHL) S&P BSE Sensex S&P Small-Cap 600
YTD-50.10-8.79-19.61
1 month0.81-4.72-9.38
3 months-17.76-12.34-15.04
1 Year-74.231.24-17.73
3 Years--10.015.82
5 Years--11.235.47
10 Years--11.779.50
As on 05-Jul-2022